Organisation paid for research Program year 2023 Source: CMS Open Payments

Ark

Neither a doctor nor a teaching hospital

Research payments

$3,252,140

93 payments

Through program year 2023, Ark is reported as receiving $3,252,140 in research payments, across 93 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$664,401	16
2022	Research	$307,694	12
2021	Research	$1,982,049	30
2020	Research	$295,662	12
2019	Research	$2,334	23

Breakdown

Who paid Research payments · program years 2019–2023

Regeneron Pharmaceuticals, Inc. $3,231,805 68 payments
Cipla USA Inc. $20,334 25 payments

Studies the money was for Research payments · program years 2019–2023

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $2,698,218 37 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $418,984 13 payments
A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $73,191 4 payments
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease $24,000 5 payments
A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-Week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 Micro GM Inhalation Powder With Advair Diskus 100/50 Micro GM in Asthma Patients $18,000 2 payments
Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA) $17,411 9 payments
U-Fs-Mu-As3120 $2,334 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.